You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ovarian cancer (PARP-failure)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Drug Related Tumor/Cancer Trial (secondary cytoreductive surgery, chemo)

Not yet recruiting
  • Ovarian Cancer
  • Drug Related Neoplasm/Cancer
  • (no location specified)
Jan 28, 2023

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Cancer Trial in Madrid (Exercise and dietary recommendations)

Not yet recruiting
  • Ovarian Cancer
  • Exercise and dietary recommendations
  • Madrid, Spain
  • +3 more
Nov 15, 2023

Ovarian Cancer Trial (JPI-547)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 24, 2022

Cytotoxic Chemotherapy and PARP Inhibition on Genomic Contexture

Recruiting
  • Ovarian Cancer
    • Athens, Greece
      Adamantia Nikolaidi
    Aug 9, 2022

    Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

    Recruiting
    • Ovarian Carcinoma
    • Biospecimen Collection
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 5, 2023

    Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

    Terminated
    • Ovarian Neoplasms
    • +3 more
    • AK112 low dose
    • +2 more
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Oct 8, 2022

    Breast Cancer After Ovarian Cancer During and/or After Therapy:

    Recruiting
    • BRCA-Associated Breast Carcinoma
    • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Mar 9, 2023

    Ovarian Cancer Recurrent Trial in Sutton, London (Niraparib oral capsule, SBRT)

    Not yet recruiting
    • Ovarian Cancer Recurrent
    • Niraparib oral capsule
    • SBRT
    • Sutton, Surrey, United Kingdom
    • +1 more
    Aug 10, 2023

    Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • (no location specified)
    Aug 8, 2022

    Ovarian Cancer, Fatigue, Coping Behavior Trial in Boston, Philadelphia (Enhanced Usual Care (EOC), REVITALIZE ACT Intervention)

    Active, not recruiting
    • Ovarian Cancer
    • +3 more
    • Enhanced Usual Care (EOC)
    • REVITALIZE ACT Intervention
    • Boston, Massachusetts
    • +1 more
    Jun 13, 2022

    Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

    Recruiting
    • Platinum-Refractory Fallopian Tube Carcinoma
    • +11 more
    • Copanlisib Hydrochloride
    • +4 more
    • Aurora, Colorado
    • +2 more
    Dec 8, 2022

    Epithelial Ovarian Cancer Eligible to PARP Inhibitors

    Recruiting
    • Ovarian Cancer
    • blood sample
    • Besançon, France
    • +1 more
    Mar 24, 2022

    Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

    Not yet recruiting
    • Breast Cancer
    • +7 more
    • (no location specified)
    Sep 26, 2023

    Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Cetntre
    Sep 25, 2023

    Ovarian Cancer, Breast Cancer, Solid Tumor Trial in Houston, Brisbane (CYH33)

    Recruiting
    • Ovarian Cancer
    • +4 more
    • New Haven, Connecticut
    • +6 more
    Oct 10, 2022

    Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

    Recruiting
    • Recurrent Fallopian Tube Carcinoma
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Jan 12, 2023

    HRD Score in Chinese Ovarian Cancer Patients Benefiting From

    Recruiting
    • Ovarian Cancer
      • Shanghai, Shanghai, China
        The Obstetrics and Gynecology Hospital of Fudan University
      Feb 24, 2022

      Ovarian Cancer Trial in Toronto (Cediranib, Olaparib)

      Completed
      • Ovarian Cancer
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      May 3, 2022

      Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Toronto (Niraparib, Dostarlimab, Bevacizumab)

      Not yet recruiting
      • Ovarian Cancer
      • +4 more
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      May 2, 2022

      Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

      Active, not recruiting
      • Fallopian Tube Endometrioid Tumor
      • +13 more
      • Orange, California
      • +19 more
      Jan 10, 2023

      Ovarian Tumor Trial in United States (Dostarlimab, Bevacizumab, Niraparib)

      Completed
      • Ovarian Neoplasm
      • Birmingham, Alabama
      • +9 more
      Feb 20, 2023

      Ovarian Cancer, Breast Cancer Trial in Dallas (Lynparza)

      Active, not recruiting
      • Ovarian Cancer
      • Breast Cancer
      • Dallas, Texas
        University of Texas Southwestern Medical Center
      Mar 22, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

      Not yet recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +3 more
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      Sep 8, 2022